User: Guest  Login
Document type:
journal article 
Untch, M; Eidtmann, H; du Bois, A; Meerpohl, HG; Thomssen, Ch; Ebert, A; Harbeck, N; Jackisch, C; Heilman, V; Emons, G; Wallwiener, D; Wiese, W; Blohmer, JU; Höffken, K; Kuhn, W; Reichardt, P; Muscholl, M; Pauschinger, M; Langer, B; Lück, HJ 
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. 
This prospective, parallel-group, dose-escalation study evaluated the cardiac safety of trastuzumab (Herceptin) plus epirubicin/cyclophosphamide (EC) in women with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer (MBC) and determined an epirubicin dose for further evaluation. HER2-positive patients received standard-dose trastuzumab plus epirubicin (60 or 90 mg/m(2))/cyclophosphamide (600 mg/m(2)) 3-weekly (EC60+H, n=26; EC90+H, n=25), for four to six cycles; 23 HER2-negative patients received EC alone (90/600 mg/m(2)) 3-weekly for six cycles (EC90). All patients underwent thorough cardiac evaluation. Two EC90+H-treated patients experienced symptomatic congestive heart failure 4.5 and 6 months after the end of chemotherapy. One EC60+H-treated patient experienced an asymptomatic decrease in left ventricular ejection fraction (LVEF) to<50% 6 months after the end of chemotherapy. No such events occurred in control patients. Asymptomatic LVEF decreases of>10% points were detected in 12 (48%), 14 (56%) and 5 (24%) patients treated with EC60+H, EC90+H, and EC90. Objective response rates with EC60+H and EC90+H were>60%, and 26% for EC90 alone. These results indicate that trastuzumab may be combined with EC with manageable cardiotoxicity and promising efficacy. 
Journal title abbreviation:
Eur J Cancer 
Journal volume:
Journal issue:
Pages contribution:
TUM Institution:
Frauenklinik und Poliklinik